Date Title Description PDF
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
12 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 5 April and 11 April 2024 Download
05 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 28 March and 4 April 2024 Download
02 Apr 2024 On business and financial situation ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia Download
29 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 March and 27 March 2024 Download
22 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 March and 21 March 2024 Download

Pages

Date Title Description PDF
21 Feb 2012 Información sobre resultados (2) Download
21 Feb 2012 Información sobre resultados Download
21 Feb 2012 Informe Anual de Gobierno Corporativo Download
15 Feb 2012 Cambios en política de inversión, áreas de negocio y líneas de productos Download
22 Dec 2011 Composición del Consejo de Administración Download

Pages